Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MannKind Corporation stock logo
MNKD
MannKind
$3.94
$3.21
$2.23
$6.51
$1.22B1.134.92 million shs16.62 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$31.85
$41.98
$23.57
$60.08
$1.29B0.46321,890 shs439,562 shs
Veru Inc. stock logo
VERU
Veru
$2.95
$2.50
$2.05
$7.33
$47.35M-1.145.67 million shs571,272 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MannKind Corporation stock logo
MNKD
MannKind
+0.51%+5.07%+33.11%+59.51%+3.41%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
+3.27%+1.89%-6.05%-37.25%+32.93%
Veru Inc. stock logo
VERU
Veru
-1.34%-9.51%+39.81%+29.96%-51.16%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MannKind Corporation stock logo
MNKD
MannKind
$3.94
$3.21
$2.23
$6.51
$1.22B1.134.92 million shs16.62 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$31.85
$41.98
$23.57
$60.08
$1.29B0.46321,890 shs439,562 shs
Veru Inc. stock logo
VERU
Veru
$2.95
$2.50
$2.05
$7.33
$47.35M-1.145.67 million shs571,272 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MannKind Corporation stock logo
MNKD
MannKind
+0.51%+5.07%+33.11%+59.51%+3.41%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
+3.27%+1.89%-6.05%-37.25%+32.93%
Veru Inc. stock logo
VERU
Veru
-1.34%-9.51%+39.81%+29.96%-51.16%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
MannKind Corporation stock logo
MNKD
MannKind
2.60
Moderate Buy$8.97127.63% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.00
Hold$42.5033.44% Upside
Veru Inc. stock logo
VERU
Veru
2.50
Moderate Buy$23.00679.66% Upside

Current Analyst Ratings Breakdown

Latest MNKD, PAHC, and VERU Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/15/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
DowngradeBuy (B-)Hold (C+)
6/4/2026
Veru Inc. stock logo
VERU
Veru
Reiterated RatingBuy$25.00
6/1/2026
MannKind Corporation stock logo
MNKD
MannKind
Set Price TargetOverweight$11.00
5/21/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
DowngradeStrong-BuyHold
5/15/2026
Veru Inc. stock logo
VERU
Veru
Lower Price TargetOutperform$25.00 ➝ $24.00
5/14/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Lower Price TargetNeutral$62.00 ➝ $44.00
5/8/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
DowngradeBuy (B)Buy (B-)
5/7/2026
MannKind Corporation stock logo
MNKD
MannKind
Boost Price TargetOverweight$8.00 ➝ $10.00
5/7/2026
MannKind Corporation stock logo
MNKD
MannKind
Boost Price TargetBuy$8.00 ➝ $10.00
5/7/2026
MannKind Corporation stock logo
MNKD
MannKind
Boost Price TargetSector Perform$3.50 ➝ $4.75
5/7/2026
MannKind Corporation stock logo
MNKD
MannKind
Lower Price TargetOutperform$8.00 ➝ $7.00
(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
MannKind Corporation stock logo
MNKD
MannKind
$348.97M3.49$0.06 per share63.35($0.17) per share-23.18
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.30B1.00$3.38 per share9.43$7.05 per share4.52
Veru Inc. stock logo
VERU
Veru
N/AN/AN/AN/A$1.25 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
MannKind Corporation stock logo
MNKD
MannKind
$5.86M-$0.07N/A32.83N/A-6.63%-11.21%-3.92%8/5/2026 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$48.26M$2.3313.679.560.476.35%37.14%8.57%6/30/2026 (Confirmed)
Veru Inc. stock logo
VERU
Veru
-$22.73M-$0.89N/AN/AN/AN/A-54.72%-39.09%8/11/2026 (Estimated)

Latest MNKD, PAHC, and VERU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026Q2 2026
Veru Inc. stock logo
VERU
Veru
-$0.2850-$0.13+$0.1550-$0.12$1.90 millionN/A
5/6/2026Q1 2026
MannKind Corporation stock logo
MNKD
MannKind
-$0.02-$0.05-$0.03-$0.05$105.38 million$90.17 million
5/6/2026Q3 2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.72$0.76+$0.04$0.59$367.02 million$383.54 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
MannKind Corporation stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.51%N/A20.60%N/A
Veru Inc. stock logo
VERU
Veru
N/AN/AN/AN/AN/A

Latest MNKD, PAHC, and VERU Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/5/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.121.51%6/3/20266/3/20266/24/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
MannKind Corporation stock logo
MNKD
MannKind
N/A
1.87
1.50
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.97
3.17
1.26
Veru Inc. stock logo
VERU
Veru
N/A
6.19
6.19

Institutional Ownership

CompanyInstitutional Ownership
MannKind Corporation stock logo
MNKD
MannKind
49.55%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
Veru Inc. stock logo
VERU
Veru
47.16%

Insider Ownership

CompanyInsider Ownership
MannKind Corporation stock logo
MNKD
MannKind
2.60%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
50.13%
Veru Inc. stock logo
VERU
Veru
14.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
MannKind Corporation stock logo
MNKD
MannKind
400308.95 million300.92 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2,47540.56 million20.23 millionOptionable
Veru Inc. stock logo
VERU
Veru
23016.05 million13.77 millionOptionable

Recent News About These Companies

Veru And 2 Other Intriguing Penny Stocks To Watch
Transcript: Veru Q2 2026 Earnings Conference Call
Veru (VERU) Q2 2026 Earnings Transcript
Veru Inc VERU

New MarketBeat Followers Over Time

Media Sentiment Over Time

MannKind stock logo

MannKind NASDAQ:MNKD

$3.94 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$3.91 -0.03 (-0.66%)
As of 06/18/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$31.85 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$31.86 +0.01 (+0.05%)
As of 06/18/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Veru stock logo

Veru NASDAQ:VERU

$2.95 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$2.96 +0.00 (+0.17%)
As of 06/18/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.